Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Mar 04 04:00PM ET
1.62
Dollar change
-0.09
Percentage change
-5.26
%
Index- P/E- EPS (ttm)-0.33 Insider Own12.08% Shs Outstand184.14M Perf Week7.28%
Market Cap305.19M Forward P/E- EPS next Y-0.27 Insider Trans-0.88% Shs Float165.62M Perf Month-5.26%
Income-61.09M PEG- EPS next Q-0.04 Inst Own20.48% Short Float4.83% Perf Quarter52.83%
Sales193.61M P/S1.58 EPS this Y39.71% Inst Trans-9.69% Short Ratio4.09 Perf Half Y16.55%
Book/sh-0.21 P/B- EPS next Y11.11% ROA-18.21% Short Interest8.00M Perf Year74.59%
Cash/sh0.25 P/C6.56 EPS next 5Y- ROE-554.87% 52W Range0.49 - 1.84 Perf YTD30.65%
Dividend Est.- P/FCF- EPS past 5Y21.17% ROI-99.37% 52W High-11.96% Beta0.77
Dividend TTM- Quick Ratio1.14 Sales past 5Y14.82% Gross Margin- 52W Low230.54% ATR (14)0.12
Dividend Ex-Date- Current Ratio1.38 EPS Y/Y TTM62.33% Oper. Margin-28.87% RSI (14)55.32 Volatility9.77% 6.90%
Employees205 Debt/Eq- Sales Y/Y TTM-34.82% Profit Margin-31.56% Recom1.00 Target Price4.33
Option/ShortYes / Yes LT Debt/Eq- EPS Q/Q72.74% Payout- Rel Volume1.54 Prev Close1.71
Sales Surprise-12.83% EPS Surprise5.88% Sales Q/Q-14.13% EarningsNov 08 BMO Avg Volume1.96M Price1.62
SMA204.28% SMA509.34% SMA20031.87% Trades Volume3,024,087 Change-5.26%
Date Action Analyst Rating Change Price Target Change
Nov-29-23Resumed BTIG Research Buy $4
Aug-28-23Upgrade H.C. Wainwright Neutral → Buy $3.75
May-31-23Upgrade Piper Sandler Neutral → Overweight $2 → $4
Mar-31-22Downgrade Piper Sandler Overweight → Neutral $8 → $2
Mar-31-22Downgrade Needham Buy → Hold
Mar-31-22Downgrade Mizuho Buy → Neutral $6 → $2
Mar-31-22Downgrade H.C. Wainwright Buy → Neutral $10 → $2
Mar-08-21Initiated Cantor Fitzgerald Overweight $8
Jan-29-21Downgrade JP Morgan Neutral → Underweight
Nov-14-19Reiterated Needham Buy $18 → $15
Mar-01-24 04:05PM
Feb-02-24 04:05PM
Jan-30-24 08:00AM
Jan-09-24 08:30AM
Jan-02-24 04:30PM
08:00AM Loading…
Dec-20-23 08:00AM
Dec-01-23 04:05PM
10:00AM
Nov-20-23 08:00AM
Nov-09-23 11:32AM
Nov-08-23 10:05PM
07:40AM
07:30AM
Nov-02-23 04:30PM
Nov-01-23 04:05PM
08:00AM Loading…
Oct-31-23 08:00AM
Oct-26-23 10:02AM
Oct-25-23 08:30AM
Oct-18-23 08:00AM
Oct-03-23 04:05PM
Sep-28-23 08:00AM
Sep-26-23 08:00AM
Sep-06-23 08:00AM
Sep-05-23 04:05PM
Aug-31-23 06:15AM
Aug-28-23 12:18PM
11:44AM
08:12AM
Aug-25-23 10:25PM
09:40AM
08:28AM Loading…
08:28AM
08:09AM
Aug-24-23 08:00AM
Aug-23-23 04:35PM
Aug-17-23 04:05PM
Aug-10-23 05:40PM
Aug-01-23 04:30PM
Jul-26-23 09:40AM
Jul-19-23 07:45AM
Jul-18-23 07:45AM
Jul-06-23 06:07AM
Jul-05-23 04:05PM
Jul-04-23 07:34AM
Jun-29-23 08:00AM
Jun-27-23 09:50AM
Jun-21-23 08:35AM
Jun-20-23 08:00AM
Jun-19-23 09:40AM
Jun-13-23 07:00AM
Jun-08-23 01:20PM
09:19AM
Jun-02-23 12:00PM
09:40AM
08:30AM
Jun-01-23 04:05PM
May-30-23 07:30AM
May-25-23 08:00AM
May-23-23 11:27AM
May-22-23 05:15PM
08:30AM
May-10-23 09:40AM
May-09-23 02:12AM
May-08-23 08:45AM
07:30AM
May-04-23 10:00AM
May-01-23 10:01AM
08:00AM
Apr-25-23 02:30PM
Apr-19-23 01:07PM
Apr-14-23 08:30AM
Apr-11-23 11:15AM
Apr-07-23 08:30AM
Apr-04-23 04:05PM
Apr-03-23 08:30AM
Mar-30-23 08:30AM
Mar-24-23 08:30AM
Mar-13-23 02:51AM
Mar-09-23 10:42PM
08:45AM
07:30AM
Mar-02-23 08:30AM
Feb-23-23 04:05PM
05:34AM
Feb-21-23 06:30AM
Feb-01-23 04:05PM
Jan-03-23 04:05PM
Dec-22-22 08:45AM
Dec-02-22 04:05PM
Nov-22-22 04:05PM
Nov-09-22 06:10AM
Nov-03-22 06:45PM
04:05PM
Nov-02-22 04:05PM
Oct-27-22 08:30AM
Oct-21-22 08:30AM
Oct-03-22 04:05PM
Sep-02-22 04:05PM
Sep-01-22 08:30AM
Aug-05-22 11:12AM
Aug-04-22 07:25PM
Akebia Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapeutics for patients with kidney diseases. The firm is also involved in the development and commercialization of drugs for the treatment of renal and metabolic disorders. Its products include Auryxia and Vadadustat. The company was founded by Joseph H. Gardner, John M. Rice, Michael E. Pape, Josh P. Fairbank, and Robert A. Shalwitz on February 27, 2007 and is headquartered in Cambridge, MA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Butler John P.CEO and PresidentFeb 29Sale1.5846,57073,5812,044,580Mar 01 05:47 PM
Dahan MichelSVP, Chief Operating OfficerFeb 29Sale1.588,66113,684706,932Mar 01 05:49 PM
Burke Steven KeithSVP, Chief Medical OfficerFeb 29Sale1.587,16911,327695,840Mar 01 05:46 PM
Hadas Nicole R.SVP, Chief Legal OfficerFeb 29Sale1.585,9749,439663,259Mar 01 05:48 PM
Butler John P.CEO and PresidentFeb 27Sale1.5237,73357,3542,091,150Feb 29 06:00 PM
Dahan MichelSVP, Chief Operating OfficerFeb 27Sale1.5210,74416,331715,593Feb 29 06:02 PM
Burke Steven KeithSVP, Chief Medical OfficerFeb 27Sale1.528,36712,718703,009Feb 29 06:01 PM
Hadas Nicole R.SVP, Chief Legal OfficerFeb 27Sale1.527,41111,265669,233Feb 29 06:03 PM
Butler John P.CEO and PresidentFeb 01Sale1.6846,48978,1022,128,883Feb 02 04:10 PM
Burke Steven KeithSVP, Chief Medical OfficerFeb 01Sale1.6824,31140,842711,376Feb 02 04:10 PM
Dahan MichelSVP, Chief Operating OfficerMay 25Sale1.2295,478116,760574,037May 25 09:01 PM
Hadas Nicole R.SVP, Chief Legal OfficerMay 25Sale1.2263,18677,270524,344May 25 09:01 PM
Burke Steven KeithSVP, Chief Medical OfficerMay 16Sale1.0763,56767,890530,487May 18 06:20 PM
Spellman David ASVP, CFO and TreasurerMay 16Sale1.0763,56767,890446,483May 18 06:19 PM